Cetuximab (IMC-C225), an anti-EGFR humanized monoclonal antibody, shows multifaceted benefit in HNSCC by blocking proliferation, angiogenesis and metastasis while increasing tumor cell apoptosis [181,182,183]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.